ArticleVirchows Archiv : an international journal of pathology2026
Role of INSM1 expression in the diagnostic work-up of pancreatic acinar cell carcinoma with special reference to the differential diagnosis with neuroendocrine tumor.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinar cell carcinomas (ACCs) of the pancreas are rare neoplasms composed of cells showing acinar cell differentiation demonstrated by the immunoreactivity for acinar cells markers including trypsin, chymotrypsin, and BCL10. The differential diagnosis with more common pancreatic neuroendocrine tumors (PanNETs) may be difficult due to some overlapping morphological features and the expression of general neuroendocrine markers (synaptophysin and chromogranin A) by acinar cells, a phenomenon observed in about 35% of cases. These tumors showing a dual acinar and neuroendocrine differentiation need to be separated from PanNETs since their clinical management and prognosis are different. Little is known about the possible diagnostic role of INSM1, a highly specific and sensitive "second generation" neuroendocrine marker recently identified. With this aim we investigated INSM1 expression in 58 ACCs that, based on the expression of synaptophysin and chromogranin A, were separated into 36 pure ACCs lacking any neuroendocrine marker expression, 21 ACCs with divergent acinar and neuroendocrine differentiation, and one mixed neuroendocrine/non-neuroendocrine neoplasm (MiNEN) consisting of two separate acinar and neuroendocrine components. INSM1 expression overlapped that of synaptophysin and chromogranin A, although in several cases the number of INSM1 positive cells was less than that of chromogranin A. In conclusion, our results show that INSM1 expression in a pancreatic neoplasm should be carefully considered and interpreted in conjunction with morphology and a comprehensive immunohistochemical panel and does not give any diagnostic advantage respect to "traditional" neuroendocrine markers.
Indexed as
Identifiers
42373833What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.